2014
DOI: 10.1002/0471141755.ph1431s67
|View full text |Cite
|
Sign up to set email alerts
|

Modeling Human Liver Cancer Heterogeneity: Virally Induced Transgenic Models and Mouse Genetic Models of Chronic Liver Inflammation

Abstract: In addition to being the most common primary liver cancer, hepatocellular carcinoma (HCC) is the second most common cause of cancer-related death in humans. Treatment options are limited for this chemoresistant cancer, with liver transplantation and surgical intervention in early stages being the most successful treatments. Drug development over the past 15 years has focused on generating mouse models that mimic the human pathology for HCC. This has enabled the laboratory testing of potentially new human thera… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2015
2015
2022
2022

Publication Types

Select...
4

Relationship

1
3

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 86 publications
0
2
0
Order By: Relevance
“…To develop a detailed understanding of the oncological functions of SAMSN1, further functional studies are required. For example, studies that aim to identify the binding partners of SAMSN1 or those that can take advantage of mouse models of GC to evaluate the effects of the presence or absence of SAMSN1 on premalignant and malignant phenotypes would be of great value in advancing our understanding of the role of this tumor suppressor in GC (40).…”
mentioning
confidence: 99%
“…To develop a detailed understanding of the oncological functions of SAMSN1, further functional studies are required. For example, studies that aim to identify the binding partners of SAMSN1 or those that can take advantage of mouse models of GC to evaluate the effects of the presence or absence of SAMSN1 on premalignant and malignant phenotypes would be of great value in advancing our understanding of the role of this tumor suppressor in GC (40).…”
mentioning
confidence: 99%
“…Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related death [ 1 ]. To date, there is no clinical evidence that most of the adjuvant agents studied can improve survival in any stage of HCC [ 2 ].…”
Section: Introductionmentioning
confidence: 99%